<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8506">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00829686</url>
  </required_header>
  <id_info>
    <org_study_id>FWH20080055H-Pilot</org_study_id>
    <nct_id>NCT00829686</nct_id>
  </id_info>
  <brief_title>Trial of Antibiotic Treatment for Skin Abscess in Patients at Risk for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection</brief_title>
  <official_title>Prospective Randomized Controlled Trial of Antibiotic Treatment for Uncomplicated Skin Abscess in Patients at Risk for Community Acquired Methicillin-Resistant Staphylococcus Aureus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wilford Hall Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wilford Hall Medical Center</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients will be enrolled in a multi-center study (WHMC and BAMC) to prospectively evaluate
      outcome after treatment for an uncomplicated skin abscess. All patients will receive
      incision and drainage and wound cultures. Patients will then be randomized to 1)no
      antibiotic or 2) bactrim DS (800/160) two tablets PO BID x 7 days. This is the dose
      recommended for treating skin and soft tissue infections. (Ellis et al. Current Opinion in
      Infectious Diseases. 18(6):496-501, December 2005) Patients will then return to the ER on
      days 3 and 7 for wound repacking and evaluation. The primary outcome is clinical cure of
      abscess at 7 days after incision and drainage and recurrence rates within 30 days of
      treatment. Patients who are not improving at the following visit will then be treated with
      additional antibiotics or admission if needed. Data will be analyzed both by initial
      randomization and intention to treat. This serves as the pilot for the full placebo
      controlled randomized trial.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Clinical Improvement at 7 Days After Incision and Drainage</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence Rates</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Abscess</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No antibiotic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Septra DS (800/160) two pills PO BID x 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Septra</intervention_name>
    <description>(800/125) PO BID X 7 days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all patients age 18-55 who present to the emergency department with a skin abscess
             that requires incision and drainage.

        Exclusion Criteria:

          -  patients with diabetes, HIV, cancer or other immunocompromised patients

          -  patients who received antibiotics within one week of presentation or were
             hospitalized in previous month will be excluded to minimize potential confounding
             variables

          -  pregnant and breastfeeding patients will also be excluded due to possible safety
             concerns with antibiotic treatment

          -  basic Military Trainees will also be excluded from participation

          -  patients with abscesses on head, face, perirectal, or periananal regions, abscesses
             with known tracks or fistulas to deeper structures, or abscesses requiring surgical
             drainage in an operating room are excluded

          -  patients with sulfa allergy will be excluded.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Wilford Hall Medical Center</name>
      <address>
        <city>Lackland Air Force Base</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <lastchanged_date>July 27, 2009</lastchanged_date>
  <firstreceived_date>January 26, 2009</firstreceived_date>
  <firstreceived_results_date>June 5, 2009</firstreceived_results_date>
  <responsible_party>
    <name_title>Dr. Gillian Schmitz</name_title>
  </responsible_party>
  <keyword>abscess</keyword>
  <keyword>cellulitis</keyword>
  <keyword>antibiotics</keyword>
  <keyword>MRSA</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Abscess</mesh_term>
    <mesh_term>Staphylococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited who presented to the ER with an uncomplicated skin abscess who met inclusion criteria and did not meet exclusion criteria. Informed consent was obtained.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>No Intervention</title>
          <description>No antibiotic</description>
        </group>
        <group group_id="P2">
          <title>Septra DS</title>
          <description>Septra DS (800/160) two pills PO BID x 7 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>No Intervention</title>
          <description>No antibiotic</description>
        </group>
        <group group_id="B2">
          <title>Septra DS</title>
          <description>Septra DS (800/160) two pills PO BID x 7 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
                <measurement group_id="B2" value="18"/>
                <measurement group_id="B3" value="31"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
                <measurement group_id="B2" value="18"/>
                <measurement group_id="B3" value="31"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Age 18-25</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="13"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Age 26-40</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="5"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Age 41-65</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
                <measurement group_id="B2" value="8"/>
                <measurement group_id="B3" value="13"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="33.4" spread="2"/>
                <measurement group_id="B2" value="34.5" spread="2"/>
                <measurement group_id="B3" value="34.3" spread="2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="14"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
                <measurement group_id="B2" value="8"/>
                <measurement group_id="B3" value="17"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
                <measurement group_id="B2" value="18"/>
                <measurement group_id="B3" value="31"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Improvement at 7 Days After Incision and Drainage</title>
        <description>improving wound without evidence of fever, worsening cellulitis or induration</description>
        <time_frame>7 days</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>No Intervention</title>
            <description>No antibiotic</description>
          </group>
          <group group_id="O2">
            <title>Septra DS</title>
            <description>Septra DS (800/160) two pills PO BID x 7 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Clinical Improvement at 7 Days After Incision and Drainage</title>
            <description>improving wound without evidence of fever, worsening cellulitis or induration</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="14"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recurrence Rates</title>
        <description>recurrence of abscess in previous or new location within 30 days</description>
        <time_frame>30 days</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>No Intervention</title>
            <description>No antibiotic</description>
          </group>
          <group group_id="O2">
            <title>Septra DS</title>
            <description>Septra DS (800/160) two pills PO BID x 7 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Recurrence Rates</title>
            <description>recurrence of abscess in previous or new location within 30 days</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gillian Schmitz, MD</name_or_title>
      <organization>Wilford Hall Medical Center</organization>
      <phone>919-724-9185</phone>
      <email>gillianmd@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
